Research Topics
| Martin SchaeferSummaryAffiliation: Humboldt University Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effectsMartin Schaefer
Charite Universitatsmedizin Berlin, Klinik und Poliklinik für Psychiatrie und Psychotherapie Campus Charité Mitte, Berlin, Germany
Hepatology 46:991-8. 2007..CONCLUSION: In an interdisciplinary treatment setting psychiatric diseases and/or drug addiction did not negatively influence psychiatric tolerability of and antiviral response rate to HCV treatment with pegIFN-alpha and ribavirin...- Memantine-associated reversal of clozapine-induced weight gainM Schaefer
Department of Psychiatry and Psychotherapy, Charite Universitatsmedizin Berlin, Campus Charite Mitte, Berlin, Germany
Pharmacopsychiatry 40:149-51. 2007..Weight gain is a frequently observed adverse event in the treatment with atypical antipsychotics that significantly affects the patients' physical health and treatment compliance... 
Three cases of successful tryptophan add-on or monotherapy of hepatitis C and IFNalpha-associated mood disordersMartin Schaefer
Department of Psychiatry, Charite Universitatsmedizin, Berlin, Germany
Psychosomatics 49:442-6. 2008..Interferon-alpha (IFN(alpha))-associated mood disorder is a major complication of treatment for chronic hepatitis C...- [Experience with new teaching methods and testing in psychiatric training]M Schafer
Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Charite Universitatsmedizin Berlin, Campus Charite Mitte, Schumannstrasse, Berlin
Nervenarzt 78:283-4, 287-90, 292-3. 2007..First positive results indicate that this course represents an appropriate and practicable curriculum for teaching psychiatry in Germany... - Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis CMartin Schaefer
Department of Psychiatry, Charite University Medicine Berlin, Campus Charite Mitte, Schumannstr 20 21, D 10117 Berlin, Germany
J Hepatol 42:793-8. 2005..We prospectively studied the efficacy of a pre-emptive treatment with the antidepressant citalopram to prevent depression during hepatitis C treatment with pegylated IFN-alpha-2b plus ribavirin... - Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alphaMartin Schaefer
Department of Psychiatry, Charite University Medicine Berlin, Campus Charite Mitte, Schumannstr 20 21, D 10117 Berlin, Germany
Brain Behav Immun 18:555-62. 2004..367, p = .018). Our data provides evidence for an association between the induction of sICAM-1 and the development of symptoms of depression during IFN-alpha treatment, possibly by enhancing BBB-permeability... - Neurotransmitter changes by interferon-alpha and therapeutic implicationsM Schaefer
Department of Psychiatry and Psychotherapy, Charite University Medicine Berlin, Campus Charité Mitte CCM, Berlin, Germany
Pharmacopsychiatry 36:S203-6. 2003..We review recent research about IFN-associated neurotransmitter changes in the central nervous system and discuss treatment strategies... - [Incidence, pathoetiology and treatment of interferon-alpha induced neuro-psychiatric side effects]M Schafer
Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Charite, Humboldt Universitat, Berlin
Fortschr Neurol Psychiatr 71:469-76. 2003..Furthermore, interdisciplinary care should improve quality of life, adherence and therapeutic outcome of interferon-alpha treated patients... - Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groupsMartin Schaefer
Department of Psychiatry, Charite, Humboldt University, Berlin, Germany
Hepatology 37:443-51. 2003..Preexisting psychiatric disorders or present methadone substitution should no longer be regarded as contraindications to treatment of chronic hepatitis C with IFN-alpha and ribavirin in an interdisciplinary setting... - Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective studyKlaus Lieb
Department of Psychiatry and Psychotherapy, University of Freiburg Medical School, Hauptstr. 5, 79104 Freiburg, Germany
Eur Psychiatry 21:204-10. 2006..We suggest close monitoring of cognitive function during IFN-alpha treatment of chronic hepatitis... - Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effectsMartin Schaefer
Department of Psychiatry and Psychotherapy, Kliniken Essen Mitte, Ev Huyssenstift, Essen, Germany
Curr Drug Abuse Rev 1:177-87. 2008..Overall, the psychiatric adverse event profile of interferon-based therapy for HCV-infected patients with drug addiction is considerable and requires active management and knowledge about psychiatric medical therapy... - Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanomaAstrid Friebe
Department of Psychiatry, Charite, Campus Mitte, Berlin, Germany
J Immunother 30:333-7. 2007..In contrast to the initial hypothesis, patients characterized by high sTNF-R1 and low sIL-6R baseline levels, indicating an anti-inflammatory condition before therapy, had a higher vulnerability for depression during IFN-alpha therapy... - Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial)Susanne Ziefle
Department of Psychiatry, Charite Campus Mitte, Charite University Medicine Berlin, Germany
J Immunother 34:403-8. 2011..Specific psychosocial care should be offered especially for patients who report lower HRQoL and emotional problems before treatment to prevent early discontinuation... - Zotepine loading in acute and severely manic patients: a pilot studyBenedikt Amann
Department of Psychiatry, University LMU Munich, Germany
Bipolar Disord 7:471-6. 2005..The aim of this study was to test the first-generation atypical antipsychotic zotepine regarding its antimanic efficacy, tolerability and to find an adequate dosage for a loading strategy... - Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?Martin Schaefer
Department of Psychiatry CCM, Charite University Medicine Berlin, Berlin, Germany
Addiction 99:1167-75. 2004.... - Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trialMartin Schaefer
Department of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen Mitte, Henricistr 92, 45136 Essen, Germany
Ann Intern Med 157:94-103. 2012..It is unclear whether antidepressants can prevent IFN-induced depression in patients without psychiatric risk factors... - Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trialSarah Heinze
Department of Psychiatry, Charite Campus Mitte, Charite University Medicine, Berlin, Germany
J Immunother 33:106-14. 2010..A higher pretreatment depression score was found to be a risk factor for an early drop-out during therapy. Pretreatment screening and an interdisciplinary care of the patients is recommended... - Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trialChristoph Richter
Department of Psychiatry and Psychotherapy, Charite Universitatsmedizin Berlin, Charite Campus Mitte, Berlin, Germany
J Clin Psychopharmacol 32:558-62. 2012..Antiepileptics have been shown to reduce alcohol intake or to prevent relapse in patients with alcoholism... - Current schizophrenia drugs: efficacy and side effectsMichael Krebs
Department of Psychiatry and Psychotherapy, , Schumannstr. 20/21, D-10117 Berlin, Germany
Expert Opin Pharmacother 7:1005-16. 2006.... - Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trialChristoph Richter
Department of Psychiatry and Psychotherapy, Charite Universitatsmedizin Berlin, Charite Campus Mitte, Germany
J Clin Psychopharmacol 30:720-5. 2010..We therefore investigated the safety and efficacy of levetiracetam (LV), a newer antiepileptic with a potentially favorable adverse-effect profile, for the treatment of AWS... - Administration of interferon-alpha in mice provokes peripheral and central modulation of immune cells, accompanied by behavioral effectsArif S Orsal
Neuropsychiatry and Laboratory of Molecular Psychiatry, Charite Universitatsmedizin Berlin, Campus Mitte, Berlin, Germany
Neuropsychobiology 58:211-22. 2008..Unfortunately, the mechanisms underlying IFN-alpha-induced depression are still not well understood... - [Systematic drug documentation]M Schaefer
Charite Universitatsmedizin, Berlin
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 48:736-41. 2005..Regardless of certain methodological limitations, these databases can also be used for health economics research and evaluation... - Bioavailability of clobetasol propionate-quantification of drug concentrations in the stratum corneum by dermatopharmacokinetics using tape strippingH Weigmann
Charite, Universitätsklinikum der Humboldt Universität zu Berlin, Klinik fur Dermatologie, Venerologie und Allergologie mit Asthmapoliklinik, Berlin, Germany
Skin Pharmacol Appl Skin Physiol 12:46-53. 1999..In general, a lateral distribution of the applied drug must be taken into account when positioning the application areas on the forearm... - Psychiatric symptoms and cognitive dysfunction caused by Epstein-Barr virus-induced encephalitisJoachim Behr
Department of Psychiatry and Psychotherapy, Charite University Medicine Berlin, Campus Charite Mitte, Schumannstr 20 21, 10117 Berlin, Germany
Eur Psychiatry 21:521-2. 2006..Clinical recovery and clearance of cerebrospinal fluid EBV DNA appeared following ganciclovir treatment within 6 weeks... - Neuroprotective agents in schizophrenia and affective disordersMichael Krebs
Department of Psychiatry and Psychotherapy, Charite Universitatsmedizin Berlin, Campus Charite Mitte, Schumannstr 20 21, D 10117 Berlin, Germany
Expert Opin Pharmacother 7:837-48. 2006..This paper reviews the current options for neuroprotective treatment approaches focusing on schizophrenia and affective disorders... - Interferon alpha (IFNalpha) and psychiatric syndromes: a reviewMartin Schaefer
Department of Psychiatry, Charit, Humboldt University, Humboldt, Germany
Prog Neuropsychopharmacol Biol Psychiatry 26:731-46. 2002..Future research should improve our understanding of the role of IFNalpha for the etiopathology of psychiatric syndromes and has an impact on treatment of IFNalpha-induced psychiatric syndromes... - Interaction of hippocampal volume and N-acetylaspartate concentration deficits in schizophrenia: a combined MRI and 1H-MRS studyAndreas Arthur Klär
Department of Psychiatry and Psychotherapy, Charite University Medicine Berlin, Campus Mitte, Berlin, Germany
Neuroimage 53:51-7. 2010..However, the possible interaction between regional NAA reduction and volume deficits has been targeted only marginally in previous investigations... - The progesterone derivative dydrogesterone down-regulates neurokinin 1 receptor expression on lymphocytes, induces a Th2 skew and exerts hypoalgesic effects in miceArif Suphi Orsal
Department of Biomedical Research, Charit, University Medicine, Berlin, Germany
J Mol Med 84:159-67. 2006..Taken together, these results clearly reveal a pathway by which dydrogesterone or progesterone respectively modulates the cross talk of the nervous, endocrine and immune systems in inflammation and pain... - Interferon-alpha, cytokines and possible implications for mood disordersMartin Schaefer
Charit, Department of Psychiatry, Humboldt-University, Berlin, Germany
Bipolar Disord 4:111-3. 2002 - Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statementMartin Schaefer
Department of Psychiatry and Psychotherapy, Charite Universitatsmedizin Berlin, Campus Charite Mitte, Berlin, Germany Department of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen Mitte, Essen, Germany Electronic address
J Hepatol 57:1379-90. 2012..The summarised current knowledge about mental health changes before and during antiviral treatment should improve interdisciplinary management of HCV infected patients... - Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on designBarbara Hummel
Stanley Foundation Bipolar Network Centers, Department of Psychiatry, LMU Munich, Germany
Bipolar Disord 4:412-7. 2002..OXC is not metabolized to the 10, 11-epoxide, which seems to be responsible for several undesirable side-effects of carbamazepine and furthermore OXC has less enzyme-inducing properties... - Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis CF Schmidt
Department of Psychiatry, Ludwig Maximilians University, Munich, Germany
Aliment Pharmacol Ther 30:1049-59. 2009..Little is known about long-term effects on mental health after treatment independent from viral response and the influence of pre-existing psychiatric risk-factors... - Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on designH C Grunze
Department of Psychiatry, LMU Munich, Germany
J Clin Psychiatry 62:464-8. 2001..A series of open studies suggests that topiramate has efficacy in bipolar disorder. To further investigate the potential value of topiramate as an antimanic agent, we conducted an open trial in 11 manic patients... - Depression during treatment with interferon alphaMartin Schaefer
Psychosomatics 45:176. 2004 - Exacerbation of Psychogenic Movement Disorder by Interferon{alpha} Treatment of Hepatitis CAdrian P Mundt
Psychosomatics 48:86-7. 2007